Angel is an Associate on the Life Sciences team and focuses on identifying and evaluating new investment opportunities.
Angel joined Frazier Healthcare Partners as an Associate in 2021 and focuses on evaluating investment opportunities in the life sciences sector. She contributed to Frazier’s investment in Sonoma Biotherapeutics and is a board observer for Radionetics Oncology, and Seraxis.
Prior to joining Frazier, Angel was an Investment Fellow with Vertex Ventures Healthcare. At Vertex, she evaluated early-stage companies pursing transformative therapeutics. In previous roles, Angel served as the Director of Research and Venture Grants at Emerson Collective, Health and as the Research Director of the Friedreich Ataxia (FA) Research Alliance. In these roles, she managed strategic deployment of capital towards emergent therapeutics for oncology and FA, respectively.
Angel received her Ph.D. in Pharmacology and Cancer Biology from Duke University, where she was a Ruth L. Kirschstein Institutional National Research Service Award Fellow of the National Heart, Lung and Blood Institute.
Duke University (Ph.D.)
University of Michigan,
Ann Arbor (B.A.)